Navigation Links
Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
Date:12/24/2013

(Boston) A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced neurological decline and preserved the quality of life in patients with familial transthyretin amyloidosis (ATTR). Diflunisal is an inexpensive and safe medication marketed over the past 40 years for arthritis and pain.

This study, published in the Dec. 25 issue of JAMA, is one of the first examples of successful repurposing of a generic drug to treat a rare disease. The National Institutes of Health (NIH) has advocated this research strategy as a way to increase the availability of treatments for rare diseases such as amyloidosis.

John Berk, MD, associate professor of medicine at BUSM and clinical director of the Amyloidosis Center, designed the trial, led the international consortium of researchers, and served as the study's corresponding author. Jeffrey Kelly, PhD, a biochemist at The Scripps Research Institute, and Peter Dyck, MD, a neurologist at Mayo Clinic Rochester, were instrumental in development of the study.

Familial amyloidosis is a rare inherited disorder in which mutated transthyretin protein aggregates in the blood and forms insoluble fibrils that cause tissue damage. Patients with hereditary ATTR amyloidosis develop debilitating peripheral and autonomic nerve damage, heart disease and weight loss. Untreated, patients die 10-15 years after disease onset. Investigators at centers in Sweden, Italy, Japan, England and the United States enrolled 130 patients between 2006 and 2010. Patients were randomized to receive diflunisal or placebo treatment for two years.

The investigators found that diflunisal dramatically inhibited the progression of neurologic disease while preserving quality of life when compared to placebo treatment. Known to physicians as Dolobid, generic diflunisal is inexpensive and readily available.

To date, no other drug treatment has achieved this level of benefit for this rare disorder.

"Our results show that diflunisal represents an alternative to liver transplantation, the current standard of care for this devastating disease," said Berk. "We hope that this study prompts the identification of other widely-used generic drugs for treatment of rare diseases."

"We are pleased and optimistic about the results of this study, and are encouraged about the potential for repurposing of generic medication to bring treatments to rare and more common diseases," said Robin Conwit, MD, a Program Director with the National Institute of Neurological Disorders and Stroke (NINDS).


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Oxygen levels increase and decrease the effectiveness of anti-inflammatory therapies
2. Researchers say tart cherries have the highest anti-inflammatory content of any food
3. Study shows Where Alzheimers starts and how it spreads
4. Wayne State cholesterol study shows algal extracts may counter effects of high fat diets
5. Telecoupling science shows Chinas forest sustainability packs global impact
6. H. pylori vaccine shows promise in mouse studies
7. Deepwater Horizon NRDA study shows possible oil impact on dolphins
8. Research shows how household dogs protect against asthma and infection
9. Harvard study shows sprawl threatens water quality, climate protection, and land conservation gains
10. Study shows first link between altitude and concussion
11. International gene therapy trial for bubble boy disease shows promising early results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017 MedNet Solutions , ... the entire spectrum of clinical research, is proud ... year for the organization in terms of corporate ... eClinical products and services. The company,s exceptional achievements ... of iMedNet ™ ...
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied Market ... the global biometric technology market is expected to generate revenue of $10.72 billion by ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... January 20, 2017 Stock-Callers.com explores ... have influenced the most recent performances of select equities. ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... Grand View Research, global Biotech market size is expected to reach $604.40 ...
(Date:1/19/2017)... , Jan 19, 2017 Research and ... by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis ... ... forecasts that the global market is projected to reach $15,737 million ... 13% from 2016 to 2022. Omic technologies segment ...
(Date:1/19/2017)... -- Research and Markets ... has announced the addition of the "Implantable ... report to their offering. Report Highlights: ... a detailed analysis on current and future market trends to identify the ... values as the base numbers Key market trends across ...
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
Breaking Biology Technology: